N-[4-[tert-butyl(dimethyl)silyl]oxy-4,4-bis(diethoxyphosphoryl)butyl]tetradecanamide | 890848-03-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机膦酸及其衍生物
• 英文名称: N-[4-[tert-butyl(dimethyl)silyl]oxy-4,4-bis(diethoxyphosphoryl)butyl]tetradecanamide
• CAS: 890848-03-0
• 化学式: C₃₂H₆₉NO₈P₂Si
• 分子量: 685.935
• InChiKey: KHMPSAQHKLZQOK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.79
• 重原子数：
  44
• 可旋转键数：
  29
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.97
• 拓扑面积：
  109
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  N-[4-[tert-butyl(dimethyl)silyl]oxy-4,4-bis(diethoxyphosphoryl)butyl]tetradecanamide 在 碘代三甲硅烷 、 四丁基氟化铵 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 4.0h， 生成 (1-Hydroxy-1-phosphono-4-tetradecanoylamino-butyl)-phosphonic acid
  参考文献：
  名称：

  Synthesis and Study of Alendronate Derivatives as Potential Prodrugs of Alendronate Sodium for the Treatment of Low Bone Density and Osteoporosis

  摘要：

  Alendronate derivatives were evaluated as potential prodrugs for the osteoporosis drug alendronate sodium in an attempt to enhance the systemic exposure after oral administration. An investigation of the chemical behavior of alendronate derivatives led to development of practical synthetic strategies and prediction of each structural class's prodrug potential. Pharmacokinetic studies of N-myristoylalendronic acid revealed that 25% have been converted in vivo after iv administration in rat, providing an important proof-of-concept for this strategy.

  DOI：

  10.1021/jm060398v
• 作为产物：
  描述：

  [4-azido-1-[[(1,1-dimethylethyl)dimethylsilyl]oxy]butylidene]bis-phosphonic acid tetraethyl ester 在 palladium on activated charcoal 氢气 、 三乙胺 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 20.0 ℃ 、344.74 kPa 条件下， 反应 17.0h， 生成 N-[4-[tert-butyl(dimethyl)silyl]oxy-4,4-bis(diethoxyphosphoryl)butyl]tetradecanamide
  参考文献：
  名称：

  Synthesis and Study of Alendronate Derivatives as Potential Prodrugs of Alendronate Sodium for the Treatment of Low Bone Density and Osteoporosis

  摘要：

  Alendronate derivatives were evaluated as potential prodrugs for the osteoporosis drug alendronate sodium in an attempt to enhance the systemic exposure after oral administration. An investigation of the chemical behavior of alendronate derivatives led to development of practical synthetic strategies and prediction of each structural class's prodrug potential. Pharmacokinetic studies of N-myristoylalendronic acid revealed that 25% have been converted in vivo after iv administration in rat, providing an important proof-of-concept for this strategy.

  DOI：

  10.1021/jm060398v

文献信息

• Synthesis and Study of Alendronate Derivatives as Potential Prodrugs of Alendronate Sodium for the Treatment of Low Bone Density and Osteoporosis
  作者：Petr Vachal、Jeffrey J. Hale、Zhe Lu、Eric C. Streckfuss、Sander G. Mills、Malcolm MacCoss、Daniel H. Yin、Kimberly Algayer、Kimberly Manser、Filippos Kesisoglou、Soumojeet Ghosh、Laman L. Alani

  DOI：10.1021/jm060398v

  日期：2006.6.1

  Alendronate derivatives were evaluated as potential prodrugs for the osteoporosis drug alendronate sodium in an attempt to enhance the systemic exposure after oral administration. An investigation of the chemical behavior of alendronate derivatives led to development of practical synthetic strategies and prediction of each structural class's prodrug potential. Pharmacokinetic studies of N-myristoylalendronic acid revealed that 25% have been converted in vivo after iv administration in rat, providing an important proof-of-concept for this strategy.